biote (BTMD) to Announce Quarterly Earnings on Wednesday

biote (NASDAQ:BTMD) will likely be announcing its Q2 2026 results after the market closes on Wednesday, August 5th. Analysts expect the company to post earnings of $0.07 per share and revenue of $46.1240 million for the quarter. Investors are encouraged to explore the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 5:00 PM ET.

biote (NASDAQ:BTMD) last announced its quarterly earnings data on Wednesday, May 6th. The company reported $0.06 earnings per share for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.03). The business had revenue of $44.94 million for the quarter, compared to analyst estimates of $46.02 million. biote had a negative return on equity of 25.72% and a net margin of 8.29%. On average, analysts expect biote to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

biote Stock Performance

Shares of NASDAQ BTMD opened at $2.22 on Wednesday. biote has a one year low of $1.27 and a one year high of $4.58. The firm has a market capitalization of $83.58 million, a P/E ratio of 4.96 and a beta of 1.66. The company’s fifty day moving average is $2.19 and its two-hundred day moving average is $2.06.

Analyst Upgrades and Downgrades

BTMD has been the subject of a number of recent research reports. Truist Financial raised shares of biote to a “strong-buy” rating in a research note on Monday, June 15th. Weiss Ratings raised biote from a “sell (d)” rating to a “sell (d+)” rating in a research note on Thursday, May 28th. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, biote presently has a consensus rating of “Moderate Buy” and an average price target of $2.75.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in BTMD. LPL Financial LLC acquired a new position in shares of biote in the fourth quarter valued at approximately $32,000. Quadrature Capital Ltd purchased a new position in shares of biote during the 4th quarter worth $38,000. Marshall Wace LLP acquired a new stake in shares of biote during the fourth quarter worth $40,000. Millennium Management LLC acquired a new stake in shares of biote during the fourth quarter worth $40,000. Finally, AQR Capital Management LLC purchased a new stake in shares of biote in the first quarter valued at $43,000. 21.68% of the stock is currently owned by hedge funds and other institutional investors.

biote Company Profile

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.